Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 9/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 2/20 | 0.34 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.34 |
| ▸ | ALPG | P10696 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7277261 | 0.73 | ALOX15 (0.52) | ALOX15SMN1; SMN2 | |
| SCHEMBL3511243 | 0.68 | ALOX15 (0.50) | ALOX15TAAR1ALDH1A1HTR1AFDPS | |
| SCHEMBL4397237 | 0.68 | — | — | |
| SCHEMBL15329166 | 0.67 | ALOX15 (1.00) | ALOX15TAAR1ALDH1A1TERTFDPS | |
| SCHEMBL7300422 | 0.67 | — | — | |
| SCHEMBL1196872 | 0.67 | HPGDS (0.51) | — | |
| SCHEMBL10529956 | 0.66 | — | — | |
| SCHEMBL2969002 | 0.66 | — | — | |
| Bromide SCHEMBL28926580 | 0.66 | — | — | |
| Hydrochloric Acid SCHEMBL28156706 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210101887-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2021-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210101887-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | MDM2, TP53, TP53BP1 | ALOX15 3115/4885TAAR1 4666/4885ALDH1A1 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.